Response to "Inhaled Zanamivir versus Oral Oseltamivir to Prevent Influenza-related Hospitalization or Death: A Nationwide Population-based Quasi-experimental Study"

Clin Infect Dis. 2022 Oct 29;75(9):1676-1677. doi: 10.1093/cid/ciac462.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antiviral Agents / therapeutic use
  • Hospitalization
  • Humans
  • Influenza, Human* / drug therapy
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Neuraminidase
  • Oseltamivir / therapeutic use
  • Zanamivir* / therapeutic use

Substances

  • Zanamivir
  • Oseltamivir
  • Antiviral Agents
  • Neuraminidase